Additionally, considering its osteogenic and anti-resorptive effects, there is potential use for Lf in combination with osteogenic anti-osteoporosis drugs including teriparatide, abaloparatide or romosozumab, whether in the form of intact Lf, enzymatically digested Lf or a bioactive peptide such as LP2. The gene discussed is RPLP2; the disease is osteoporosis.